DES editorial. Is there a survival benefit?
Thomas
Dr Martyn
DM
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000191:economics / Q000295:instrumentation*; D002317:Cardiovascular Agents / Q000008:administration & dosage; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality; D003324:Coronary Artery Disease / Q000401:mortality* / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology / Q000401:mortality; D003362:Cost-Benefit Analysis; D054855:Drug-Eluting Stents / Q000191:economics; D006801:Humans; D053208:Kaplan-Meier Estimate; D006278:Medicare / Q000706:statistics & numerical data*; D008670:Metals; D017410:Practice Guidelines as Topic; D011474:Prosthesis Design; D015203:Reproducibility of Results; D012107:Research Design; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents / Q000191:economics; D016896:Treatment Outcome; D006113:United Kingdom; D014481:United States / Q000453:epidemiology
D002317:Cardiovascular Agents; D008670:Metals; D020123:Sirolimus